10.08.2010Aurgalys and Cukierman&Co Life Sciences issued July26th, 2010, an new analyst report on BioAllianceYou are hereNewsAurgalys and Cukierman&Co Life Sciences issued July26th, 2010, an new analyst report on BioAlliance
- For Acyclovir Lauriad®, the Company has engaged discussion with European regulatory agencies and obtained a registration slot. While standard drug development usually requests a second phase III trial prior to file for market authorization, BioAlliance Pharma has initiated promising discussion with European and US agencies to recognize Acyclovir Lauriad® clinical benefits and allow a much shorter process.
- S1 2010 record turnover with €21.3 M versus €4.1 M for the same period in 2009. BioAlliance has again shown the capacity to reach on time important milestones, including its new European partnership with Therabel (March 2010), followed by the FDA approval of Loramyc®/ Oravig® (April 2010).
Find an actor